EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune and tumor-intrinsic signatures are associated with resistance and response to PD-1 blockade in cutaneous squamous cell carcinoma

Viola K DeTemple, Maximilian Beikirch, Alina C Ulama, Moritz Bergmann, Sabine Bredemeier, Vivien Schacht, Michael Sachse, Peter Mohr, Thilo Gambichler, Ralf Gutzmer, Katrin Schaper-Gerhardt iD

Cancer Immunology, Immunotherapy · 30.10.2026 · 75 (11)

DOI: 10.1007/s00262-026-04610-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 30.10.2026. Verfasst von Viola K DeTemple und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Ruhr-University Bochum, Johannes Wesling Medical Center, Campus Minden, Hans Nolte Str. 1, 32429, Minden, Germany. Hauptthemen laut MEDLINE: Cutaneous Squamous Cell Carcinoma, Skin Neoplasms, Programmed Cell Death 1 Receptor, Drug Resistance, Neoplasm. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ruhr-Universität Bochum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-PD-1 therapy has significantly improved clinical outcomes in patients with advanced cutaneous squamous cell carcinoma (cSCC); however, approximately half of patients fail to respond. This study aimed to investigate molecular mechanisms underlying therapeutic resistance and to identify predictive biomarkers.

Methods

Whole transcriptome profiling was performed using HTG EdgeSeq technology on pre-treatment cSCC samples. Clinical data and treatment outcomes were correlated with gene expression profiles, and differentially expressed genes (DEGs) were analyzed in relation to response. Moreover, promising targets were further analyzed at the protein level via immunofluorescence and immunohistochemistry.

Results

Tumors from patients achieving disease control showed a distinct immune-active transcriptional profile characterized by interferon-associated signaling, enhanced antigen presentation pathways, and cytotoxic immune activity. Consistently, IFN-γ and cytolytic activity signatures were higher in patients with favorable clinical outcomes. CIBERSORTx-based deconvolution demonstrated marked interpatient heterogeneity, with T cells, macrophages, and NK cells representing major components of the immune infiltrate, but no major differences in overall immune cell composition between patients with early and late/no progression. Histopathological assessment revealed a tendency toward higher immune cell infiltration in patients achieving disease control. Notably, elevated gene expression of SLC7A5 and SOX2 was associated with poor response and early progression. Also, at protein level, higher SLC7A5 expression was associated with early progression, whereas SOX2 showed a more heterogeneous pattern, with particularly high expression in a subset of progressive tumors.

Conclusion

Our data provide hypothesis-generating evidence that a combination of immune-related and tumor-intrinsic novel molecular markers is associated with response to anti-PD-1 therapy in advanced cSCC, thereby identifying promising candidate biomarkers, which require validation in larger independent cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cutaneous Squamous Cell CarcinomaSkin NeoplasmsProgrammed Cell Death 1 ReceptorDrug Resistance, NeoplasmImmune Checkpoint InhibitorsCarcinoma, Squamous CellHumansFemaleMaleBiomarkers, TumorGene Expression ProfilingGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

BiomarkerCemiplimabCutaneous squamous cell carcinomaPD-1 inhibitorcSCC

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Dermatology, Ruhr-University Bochum, Johannes Wesling Medical Center, Campus Minden, Hans Nolte Str. 1, 32429, Minden, Germany.
  • Department of Dermatology, Allergy and Venerology, Hannover Medical School, Hannover, Germany.
  • Department of Dermatology, Klinikum Bremerhaven, Bremerhaven, Germany.
  • Department of Dermatology, Elbe Kliniken Buxtehude, Buxtehude, Germany.
  • Department of Dermatology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
  • Department of Dermatology, Dortmund Hospital gGmbH, University Witten, Herdecke, Germany.

ORCID-Profile: Katrin Schaper-Gerhardt

Förderung

  • Ruhr-Universität Bochum

Zitieren

APA

DeTemple, V. K., Beikirch, M., Ulama, A. C., Bergmann, M., Bredemeier, S., Schacht, V., Sachse, M., Mohr, P., Gambichler, T., Gutzmer, R., & Schaper-Gerhardt, K. (2026). Immune and tumor-intrinsic signatures are associated with resistance and response to PD-1 blockade in cutaneous squamous cell carcinoma. Cancer Immunology, Immunotherapy, 75(11). https://doi.org/10.1007/s00262-026-04610-w

Vancouver

DeTemple VK, Beikirch M, Ulama AC, Bergmann M, Bredemeier S, Schacht V, et al. Immune and tumor-intrinsic signatures are associated with resistance and response to PD-1 blockade in cutaneous squamous cell carcinoma. Cancer Immunology, Immunotherapy. 2026;75(11). doi:10.1007/s00262-026-04610-w

BibTeX
@article{DeTemple2026,
  author = {DeTemple, Viola K and Beikirch, Maximilian and Ulama, Alina C and Bergmann, Moritz and Bredemeier, Sabine and Schacht, Vivien and Sachse, Michael and Mohr, Peter and Gambichler, Thilo and Gutzmer, Ralf and Schaper-Gerhardt, Katrin},
  title = {Immune and tumor-intrinsic signatures are associated with resistance and response to PD-1 blockade in cutaneous squamous cell carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {11},
  doi = {10.1007/s00262-026-04610-w}
}
Kostenlos starten →